Comment on “Effectiveness of 190 µg Fluocinolone Acetonide versus 700 µg Dexamethasone Intravitreal Implants in Diabetic Macular Edema Using the Area-Under-the-Curve Method: The CONSTANT Analysis” [Response to Letter]

This article was published in the following Dove Press journal:
Clinical Ophthalmology

Javier Zarranz-Ventura ¹
Joshua O Mali ²

¹Institut Clínic d'Oftalmologia (ICOF), Hospital Clinic, Barcelona, Spain; ²The Eye Associates, Sarasota, FL, USA

Dear editor

With interest, we read the letter to the Editor regarding the Effectiveness of 190 µg fluocinolone acetonide versus 700 µg dexamethasone intravitreal implants in diabetic macular edema using the area-under-the-curve method: The CONSTANT analysis by Stewart and Taylor published in *Clinical Ophthalmology*. The key concerns raised by the authors relate to the design deficiencies of the MEAD studies¹ and highlight two specific issues – the six month dosing of the dexamethasone implant and the potentially delayed removal of cataracts.

We acknowledge that both concerns raised will have impacted the visual outcomes reported in the MEAD trial and may have therefore affected the area-under-the-curve (AUC) analysis for the dexamethasone implant in the analysis which aimed to compare the long-term effectiveness of the 190 µg fluocinolone acetonide and 700 µg dexamethasone intravitreal implants based on their supporting pivotal studies.^{1,2} However, we would like to highlight that the retreatment for the dexamethasone implant is based on the six month time point and that this is in-line with the approved usage for the dexamethasone in Europe³ (although the USA label is not as restrictive) and is based on the inclusion criteria in the MEAD studies – ie, “patients who met eligibility criteria could be retreated no more often than every 6 months; maximum of 7 treatments over 3 years.”¹ As Stewart and Taylor comment in their letter and as we stated in our original manuscript, we definitely agree that this retreatment criteria may have impacted the visual acuity outcomes observed in the MEAD trial. However, these methodologic deficiencies unfortunately cannot be controlled further, as these are indeed the trial results. The purpose of our study was to compare the visual outcomes of both trials with an AUC analysis approach, and we believe that our conclusions are in-line with this comparison and driven by the trial designs.

The second point concerned the delayed removal of the cataracts. Yang et al⁴ analysed the long-term outcomes of phakic patients with diabetic macular edema in the FAME studies and reported that the median time to development of cataract was 12 months and that the median time to extraction was 18 months,⁴ with most

Correspondence: Javier Zarranz-Ventura
Institut Clínic d'Oftalmologia (ICOF),
Hospital Clinic, Barcelona, Spain
Tel +34 932 279 391
Email jzarranz@hotmail.com

cataract extractions being completed by year two.⁵ The MEAD studies also observed an increase in the incidence of cataract surgery from year one with surgeries being conducted between months 18 and 30 (ie, a further 6 months to that reported in the FAME studies). With this data in mind, the delayed time to cataract surgery may support the need for a timelier intervention to provide better, long-term visual outcomes for the patient.

In summary, we do acknowledge that the AUC analysis does have limitations and that these have been acknowledged in the manuscript and are based on the retrospective nature of the analysis as well as the comparison of different study protocols and patients.⁶ However, the 190 µg fluocinolone acetonide implant's constant and near zero-order drug release kinetics⁷ means it is less affected by the timing of appointments and delayed injections, and is a key design feature that has long-term benefits for patients with diabetic macular edema.

Disclosure

The authors acknowledge the following financial interests: JZ-V: Alcon: Speaker, travel grant; Alimera Sciences: Consultant, speaker, travel grant; Allergan: Consultant, speaker, travel grant, grant recipient; Bausch and Lomb: Speaker, travel grant; Bayer: Consultant, speaker, travel grant; Brill Pharma: Consultant, speaker; D.O.R.C: Travel grant; Novartis: Consultant, speaker, travel grant, grant

recipient; Topcon: Speaker, travel grant; Zeiss: Speaker. JM: Alimera Sciences: Consultant, Speaker, Stock Shareholder; Allergan: Consultant, Research Funding/Grant. The authors report no other potential conflicts of interest for this communication.

References

1. Boyer DS, Yoon YH, Belfort R, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. *Ophthalmology*. 2014;121:1904–1914. doi:10.1016/j.ophtha.2014.04.024
2. Campochiaro PA, Brown DM, Pearson A, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. *Ophthalmology*. 2012;119:2125–2132. doi:10.1016/j.ophtha.2012.04.030
3. European Medicines Agency (EMA). Ozurdex. Assessment report. ozurdex-epar-summary-public_en.pdf. 2014.
4. Yang Y, Bailey C, Holz FG, et al. Long-term outcomes of phakic patients with diabetic macular oedema treated with intravitreal fluocinolone acetonide (FAc) implants. *Eye*. 2015;29:1173–1180. doi:10.1038/eye.2015.98
5. Cunha-Vaz J, Ashton P, Iezzi R, et al. Sustained delivery fluocinolone acetonide vitreous implants: long-term benefit in patients with chronic diabetic macular edema. *Ophthalmology*. 2014;121:1892–1903. doi:10.1016/j.ophtha.2014.04.019
6. Zarranz-Ventura J, Mali JO. Effectiveness of 190 µg fluocinolone acetonide and 700 µg dexamethasone intravitreal implants in diabetic macular edema using the area-under-the-curve method: the CONSTANT analysis. *Clin Ophthalmol*. 2020;14:1697–1704. doi:10.2147/OPTH.S253370
7. Campochiaro PA, Nguyen QD, Hafiz G, et al. Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants. *Ophthalmology*. 2013;120:583–587. doi:10.1016/j.ophtha.2012.09.014

Dove Medical Press encourages responsible, free and frank academic debate. The content of the Clinical Ophthalmology 'letters to the editor' section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Clinical Ophthalmology editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.

Clinical Ophthalmology

Dovepress

Publish your work in this journal

Clinical Ophthalmology is an international, peer-reviewed journal covering all subspecialties within ophthalmology. Key topics include: Optometry; Visual science; Pharmacology and drug therapy in eye diseases; Basic Sciences; Primary and Secondary eye care; Patient Safety and Quality of Care Improvements. This journal is indexed on PubMed

Central and CAS, and is the official journal of The Society of Clinical Ophthalmology (SCO). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/clinical-ophthalmology-journal>